P. J. Sterk (Amsterdam, The Netherlands), R. Buhl (Mainz, Germany)
Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler
D. Gjaltema, P. Hagedoorn, F. Grasmeijer, B. G. Huijbers, H. W. Frijlink, A. H. de Boer (Groningen, Netherlands)
|  |
QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD
R. Dahl, N. Gallagher, Y. Green, H. Bryant, H. Chen, P. D'Andrea, V. Alagappan, D. Banerji (Aarhus, Denmark; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
D. A. Mahler, M. Decramer, A. D'Urzo, H. Worth, T. White, V. Alagappan, H. Chen, K. Kulich, N. Gallagher, D. Banerji (Hanover, East Hanover, United States Of America; Leuven, Belgium; Toronto, Canada; Fürth, Germany; Basel, Switzerland; Horsham, United Kingdom)
|  |
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
D. Banerji, V. Alagappan, Y. Green, N. Gallagher, A. FowlerTaylor, P. D'Andrea, H. Chen (East Hanover, United States Of America; Horsham, United Kingdom)
| |
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
D. Banerji, V. Alagappan, Y. Green, N. Gallagher, A. FowlerTaylor, P. D'Andrea, H. Chen (East Hanover, United States Of America; Horsham, United Kingdom)
| |
Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study
M. Decramer, J. A. Wedzicha, J. H. Ficker, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Leuven, Belgium; London, United Kingdom; Nuernberg, Germany; East Hanover, United States Of America)
| |
Once-daily QVA149 provides the same efficacy as the free combination of its monocomponents indacaterol and glycopyrronium: The BEACON study
R. Dahl, D. Jadayel, V. Alagappan, H. Chen, D. Banerji (Aarhus, Denmark; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study
R. Dahl, D. Jadayel, V. Alagappan, H. Chen, D. Banerji (Aarhus, Denmark; Horsham, United Kingdom; East Hanover, United States Of America)
| |
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study
K. Asai, Y. Minakata, K. Hirata, Y. Fukuchi, T. Kitawaki, K. Ikeda, D. Banerji (Osaka, Wakayama, Tokyo, Japan; East Hanover, United States Of America)
| |
Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD
M. Moretti, A. Montagna (Carrara, Paderno Dugnano, Italy)
| |
High-dose N-acetylcysteine in the prevention of COPD exacerbations: Results of the PANTHEON study
J. P. Zheng, F. Q. Wen, C. X. Bai, H. Y. Wan, J. Kang, P. Chen, W. Z. Yao, L. J. Ma, X. Li, Y. Gao, N. S. Zhong (Guangzhou, Chengdu, Shanghai, Shenyang, Beijing, Zhengzhou, China)
| |
SPARTA: Efficacy and safety assessment of two regimens of alpha1-proteinase inhibitor in emphysema due to alpha1-antitrypsin deficiency
M. Forshag, S. Camprubi, R. Griffin, J. Chen, J. Ayguasanosa, S. Sorrells (Research Triangle Park, United States Of America; Barcelona, Spain)
| |
Add-on effects of long-acting beta2-agonists salmeterol inhaler vs tulobuterol patch in adult patients with mild-to-moderate asthma
H. Inoue, A. Niimi, H. Matsumoto, I. Ito, T. Oguma, K. Otsuka, T. Takeda, H. Nakaji, T. Tajiri, T. Iwata, T. Nagasaki, M. Mishima (Kyoto, Nagoya, Japan)
| |
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma
W. W. Busse, E. D. Bateman, P. M. O'Byrne, J. Lötvall, A. Woodcock, H. Medley, R. Forth, L. Jacques, E. R. Bleecker (Winston-Salem, Research Triangle Park, United States Of America; Cape Town, South Africa; Hamilton, Canada; Gothenburg, Sweden; Manchester, London, United Kingdom)
| |
Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma
A. Woodcock, J. Lötvall, E. R. Bleecker, W. W. Busse, P. M. O'Byrne, E. D. Bateman, S. Stone, A. Ellsworth, L. Jacques (Manchester, London, United Kingdom; Gothenburg, Sweden; Winston-Salem, Madison, Durham, United States Of America; Hamilton, Canada; Cape Town, South Africa)
| |
Comparable effectiveness of budesonide/formoterol combination and fluticasone for the treatment of cough variant asthma
S. Kirishi, E. Tagaya, M. Ishii, K. Takeyama, K. Isono, M. Kondo, F. Shinya, J. Tamaoki (Tokyo, Fukushima, Japan)
| |
The effect of inhaled ciclesonide on airway blood flow
L. A. Toth, H. Goldstein, A. Kis, L. Kunos, J. Varga, G. Losonczy, S. Vasas, E. Mendes, A. Wanner, G. Horvath (Budapest, Hungary; Miami, United States Of America)
| |
The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects
M. Fitzgerald, S. Snape, S. Febbraro, D. Singh, C. Patwell, B. Ruparelia, N. Snell (Slough, Merthyr Tydfil, Manchester, United Kingdom)
| |